Structure via PubChem · Public domain (PubChem)
nizatidine
Sign in to saveAlso known as Axid®, LY-139037, Tazac
Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.
In the Vinony graph
Within Vinony's link graph, nizatidine is referenced by 395 other articles, and connects out to peptic ulcer disease, United States Food and Drug Administration and roxatidine acetate.
Vinony files it under Drugboxes which contain changes to verified fields, Drugs developed by Eli Lilly and Company and ECHA InfoCard ID from Wikidata.
Its subject is documented across 19 Wikipedia language editions.
Chemical data
- Formula
- C12H21N5O2S2
- Molecular weight
- 331.5 g/mol
- IUPAC name
- 1-N'-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
- SMILES
- CNC(=C[N+](=O)[O-])NCCSCC1=CSC(=N1)CN(C)C
- InChIKey
- SGXXNSQHWDMGGP-UHFFFAOYSA-N
- XLogP
- 1.6
- Polar surface area
- 140 Ų
- H-bond donors
- 2
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 331.113667
- Has use
- medication
Show 4 more facts
- chemical formula
- C₁₂H₂₁N₅O₂S₂
- subject has role
- H2 antagonists
- canonical SMILES
- CNC(=C[N+](=O)[O-])NCCSCC1=CSC(=N1)CN(C)C
- Commons category
- Nizatidine
via Wikidata · CC0
~2 min read
Encyclopedic overview
6 sectionsContents
- Medical use
- Adverse effects
- History and development
- Society and culture
- Brand names
- References
Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.
It was patented in 1980 and approved for medical use in 1988. It was developed by Eli Lilly.
Excerpted from Wikipedia’s “nizatidine” article, available under the CC BY-SA 4.0 licence.